1
|
Kroll T, Miranda A, Drechsel A, Beer S, Lang M, Drzezga A, Rosa-Neto P, Verhaeghe J, Elmenhorst D, Bauer A. Dynamic neuroreceptor positron emission tomography in non-anesthetized rats using point source based motion correction: A feasibility study with [ 11C]ABP688. J Cereb Blood Flow Metab 2024; 44:1852-1866. [PMID: 38684219 DOI: 10.1177/0271678x241239133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/02/2024]
Abstract
To prevent motion artifacts in small animal positron emission tomography (PET), animals are routinely scanned under anesthesia or physical restraint. Both may potentially alter metabolism and neurochemistry. This study investigates the feasibility of fully awake acquisition and subsequent absolute quantification of dynamic brain PET data via pharmacokinetic modelling in moving rats using the glutamate 5 receptor radioligand [11C]ABP688 and point source based motion correction. Five male rats underwent three dynamic [11C]ABP688 PET scans: two test-retest awake PET scans and one scan under anesthesia for comparison. Specific radioligand binding was determined via the simplified reference tissue model (reference: cerebellum) and outcome parameters BPND and R1 were evaluated in terms of stability and reproducibility. Test-retest measurements in awake animals gave reliable results with high correlations of BPND (y = 1.08 × -0.2, r = 0.99, p < 0.01) and an acceptable variability (mean over all investigated regions 15.7 ± 2.4%). Regional [11C]ABP688 BPNDs under awake and anesthetized conditions were comparable although in awake scans, absolute radioactive peak uptakes were lower and relative blood flow in terms of R1 was higher. Awake small animal PET with absolute quantification of neuroreceptor availability is technically feasible and reproducible thereby providing a suitable alternative whenever effects of anesthesia are undesirable, e.g. in sleep research.
Collapse
Affiliation(s)
- Tina Kroll
- Institute of Neurosciences and Medicine (INM-2), Forschungszentrum Jülich GmbH, Germany
| | - Alan Miranda
- Molecular Imaging Center Antwerp, University of Antwerp, Belgium
| | - Alexandra Drechsel
- Institute of Neurosciences and Medicine (INM-2), Forschungszentrum Jülich GmbH, Germany
| | - Simone Beer
- Institute of Neurosciences and Medicine (INM-2), Forschungszentrum Jülich GmbH, Germany
| | - Markus Lang
- Institute of Neurosciences and Medicine (INM-5), Forschungszentrum Jülich GmbH, Germany
| | - Alexander Drzezga
- Institute of Neurosciences and Medicine (INM-2), Forschungszentrum Jülich GmbH, Germany
- Department of Nuclear Medicine, University Hospital Cologne, Germany
- German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany
| | - Pedro Rosa-Neto
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Canada
| | - Jeroen Verhaeghe
- Molecular Imaging Center Antwerp, University of Antwerp, Belgium
| | - David Elmenhorst
- Institute of Neurosciences and Medicine (INM-2), Forschungszentrum Jülich GmbH, Germany
- Department of Nuclear Medicine, University Hospital Cologne, Germany
| | - Andreas Bauer
- Institute of Neurosciences and Medicine (INM-2), Forschungszentrum Jülich GmbH, Germany
| |
Collapse
|
3
|
Glorie D, Servaes S, Verhaeghe J, Wyckhuys T, Wyffels L, Vanderveken O, Stroobants S, Staelens S. MicroPET Outperforms Beta-Microprobes in Determining Neuroreceptor Availability under Pharmacological Restriction for Cold Mass Occupancy. Front Neurosci 2017; 11:47. [PMID: 28239334 PMCID: PMC5301012 DOI: 10.3389/fnins.2017.00047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 01/23/2017] [Indexed: 11/13/2022] Open
Abstract
Both non-invasive micro-positron emission tomography (μPET) and in situ beta-microprobes have the ability to determine radiotracer kinetics and neuroreceptor availability in vivo. Beta-microprobes were proposed as a cost-effective alternative to μPET, but literature revealed conflicting results most likely due to methodological differences and inflicted tissue damage. The current study has three main objectives: (i) evaluate the theoretical advantages of beta-microprobes; (ii) perform μPET imaging to assess the impact of (beta-micro)probe implantation on relative tracer delivery (R1) and receptor occupancy (non-displaceable binding potential, BPND) in the rat brain; and (iii) investigate whether beta-microprobe recordings produce robust results when a pharmacological restriction for cold mass dose (tracer dose condition) is imposed. We performed acquisitions (n = 61) in naive animals, dummy probe implanted animals (outer diameter: 0.75 and 1.00 mm) and beta-microprobe implanted animals (outer diameter: 0.75 mm) using two different radiotracers with high affinity for the striatum: [11C]raclopride (n = 29) and [11C]ABP688 (n = 32). In addition, acquisitions were completed with or without an imposed restriction for cold mass occupancy. We estimated BPND and R1 values using the simplified reference tissue method (SRTM). [11C]raclopride dummy μPET BPND (0.75 mm: −13.01 ± 0.94%; 1.00 mm: −13.89 ± 1.20%) and R1 values (0.75 mm: −29.67 ± 4.94%; 1.00 mm: −39.07 ± 3.17%) significantly decreased at the implant side vs. the contralateral intact side. A similar comparison for [11C]ABP688 dummy μPET, demonstrated significantly (p < 0.05) decreased BPND (−19.09 ± 2.45%) and R1 values (−38.12 ± 6.58%) in the striatum with a 1.00 mm implant, but not with a 0.75 mm implant. Particularly in tracer dose conditions, despite lower impact of partial volume effects, beta-microprobes proved unfit to produce representative results due to tissue destruction associated with probe insertion. We advise to use tracer dose μPET to obtain accurate results concerning receptor availability and tracer delivery, keeping in mind associated partial volume effects for which it is possible to correct.
Collapse
Affiliation(s)
- Dorien Glorie
- Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of Antwerp Antwerp, Belgium
| | - Stijn Servaes
- Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of Antwerp Antwerp, Belgium
| | - Jeroen Verhaeghe
- Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of Antwerp Antwerp, Belgium
| | - Tine Wyckhuys
- Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of Antwerp Antwerp, Belgium
| | - Leonie Wyffels
- Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of AntwerpAntwerp, Belgium; Nuclear Medicine Department, Antwerp University HospitalAntwerp, Belgium
| | - Olivier Vanderveken
- Translational Neurosciences, Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital Antwerp, Belgium
| | - Sigrid Stroobants
- Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of AntwerpAntwerp, Belgium; Nuclear Medicine Department, Antwerp University HospitalAntwerp, Belgium
| | - Steven Staelens
- Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of Antwerp Antwerp, Belgium
| |
Collapse
|
4
|
de Witte WEA, Wong YC, Nederpelt I, Heitman LH, Danhof M, van der Graaf PH, Gilissen RAHJ, de Lange ECM. Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients. Expert Opin Drug Discov 2015; 11:45-63. [PMID: 26484747 DOI: 10.1517/17460441.2016.1100163] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Drug-target binding kinetics are major determinants of the time course of drug action for several drugs, as clearly described for the irreversible binders omeprazole and aspirin. This supports the increasing interest to incorporate newly developed high-throughput assays for drug-target binding kinetics in drug discovery. A meaningful application of in vitro drug-target binding kinetics in drug discovery requires insight into the relation between in vivo drug effect and in vitro measured drug-target binding kinetics. AREAS COVERED In this review, the authors discuss both the relation between in vitro and in vivo measured binding kinetics and the relation between in vivo binding kinetics, target occupancy and effect profiles. EXPERT OPINION More scientific evidence is required for the rational selection and development of drug-candidates on the basis of in vitro estimates of drug-target binding kinetics. To elucidate the value of in vitro binding kinetics measurements, it is necessary to obtain information on system-specific properties which influence the kinetics of target occupancy and drug effect. Mathematical integration of this information enables the identification of drug-specific properties which lead to optimal target occupancy and drug effect in patients.
Collapse
Affiliation(s)
- Wilhelmus E A de Witte
- a Division of Pharmacology, Leiden Academic Centre for Drug Research , Leiden University , Einsteinweg 55, 2333 CC Leiden , The Netherlands
| | - Yin Cheong Wong
- a Division of Pharmacology, Leiden Academic Centre for Drug Research , Leiden University , Einsteinweg 55, 2333 CC Leiden , The Netherlands
| | - Indira Nederpelt
- b Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research , Leiden University , Einsteinweg 55, 2333 CC Leiden , The Netherlands
| | - Laura H Heitman
- b Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research , Leiden University , Einsteinweg 55, 2333 CC Leiden , The Netherlands
| | - Meindert Danhof
- a Division of Pharmacology, Leiden Academic Centre for Drug Research , Leiden University , Einsteinweg 55, 2333 CC Leiden , The Netherlands
| | - Piet H van der Graaf
- a Division of Pharmacology, Leiden Academic Centre for Drug Research , Leiden University , Einsteinweg 55, 2333 CC Leiden , The Netherlands
| | - Ron A H J Gilissen
- c A Division of Janssen Pharmaceutica N.V., Janssen Research and Development , Turnhoutseweg 30, Beerse 2340 , Belgium
| | - Elizabeth C M de Lange
- a Division of Pharmacology, Leiden Academic Centre for Drug Research , Leiden University , Einsteinweg 55, 2333 CC Leiden , The Netherlands
| |
Collapse
|
5
|
Balasse L, Maerk J, Pain F, Genoux A, Fieux S, Lefebvre F, Morel C, Gisquet-Verrier P, Lanièce P, Zimmer L. PIXSIC: A Wireless Intracerebral Radiosensitive Probe in Freely Moving Rats. Mol Imaging 2015. [DOI: 10.2310/7290.2015.00020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Laure Balasse
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Julia Maerk
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Frédéric Pain
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Aurelie Genoux
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Sylvain Fieux
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Françoise Lefebvre
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Christian Morel
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Pascale Gisquet-Verrier
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Philippe Lanièce
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| | - Luc Zimmer
- From IMNC, CNRS, Université Paris Diderot, Université Paris Sud, Orsay, France; Lyon Neuroscience Research Center, INSERM, CNRS, Université Claude Bernard Lyon 1, France; Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, Marseille, France; Paris Sud Neuroscience Center, CNRS, Universiteé Paris Sud, Orsay, France; and Hospices Civils de Lyon, Lyon, France
| |
Collapse
|